Anti-inflammatory properties of a prostaglandin antagonist, a corticosteroid and indomethacin in experimental contact dermatitis.
The topical effects of N0164 (a phenyl phosphonate derivative which is a partially selective antagonist of prostagladin E2), indomethacin and triamcinolone acetonide have been shown to reduce the erythema and ear weight gain from inflammation induced by experimental contact allergic eczema. Oxazolone sensitized Swiss Webster mice were used, ear erythema and ear weights being used as a measure of the anti-inflammatory response to the drugs. N0164 was also shown to have systemic anti-inflammatory activity after intraperitoneal injection.
D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003877:Dermatitis, Contact / Q000139:chemically induced / Q000188:drug therapy*; D004890:Erythema / Q000188:drug therapy; D007213:Indomethacin / Q000627:therapeutic use*; D007249:Inflammation / Q000188:drug therapy; D007274:Injections, Intraperitoneal; D051379:Mice; D063065:Organophosphonates / Q000627:therapeutic use*; D010081:Oxazolone; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
D000893:Anti-Inflammatory Agents; D063065:Organophosphonates; D011448:Prostaglandin Antagonists; D010081:Oxazolone; D014222:Triamcinolone Acetonide; D007213:Indomethacin